These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12569241)

  • 21. [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].
    Scholze J; Unger T
    Internist (Berl); 2003 Sep; 44(9):1193-5. PubMed ID: 14566471
    [No Abstract]   [Full Text] [Related]  

  • 22. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALLHAT finds diuretics best for initial hypertension therapy.
    Traynor K
    Am J Health Syst Pharm; 2003 Feb; 60(3):222, 224. PubMed ID: 12613228
    [No Abstract]   [Full Text] [Related]  

  • 24. A family physician questions the conclusions from ALLHAT.
    Standridge JB
    Am J Hypertens; 2004 Apr; 17(4):361-5. PubMed ID: 15062891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALLHAT, or the soft science of the secondary end point.
    Neely DB
    Ann Intern Med; 2004 Jul; 141(1):77. PubMed ID: 15238380
    [No Abstract]   [Full Text] [Related]  

  • 26. ALLHAT: setting the record straight.
    Davis BR; Furberg CD; Wright JT; Cutler JA; Whelton P;
    Ann Intern Med; 2004 Jul; 141(1):39-46. PubMed ID: 15238369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug treatment of hypertension. Conclusion of editorial is somewhat flawed.
    Hackam DG
    BMJ; 2003 Apr; 326(7392):764. PubMed ID: 12676853
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug treatment of hypertension: implications of ALLHAT.
    Williams B
    Heart; 2003 Jun; 89(6):589-90. PubMed ID: 12748205
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R
    Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary: The ALLHAT Study: implications for the management of resistant hypertension.
    Singer GM; Setaro JF
    J Clin Hypertens (Greenwich); 2005 Jan; 7(1):31-2. PubMed ID: 15655384
    [No Abstract]   [Full Text] [Related]  

  • 33. ALLHAT: what has it taught us so far?
    Leenen FH
    CMAJ; 2004 Sep; 171(7):719-20. PubMed ID: 15451829
    [No Abstract]   [Full Text] [Related]  

  • 34. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Taylor AL; Wright JT
    Circulation; 2005 Dec; 112(23):3654-60; discussion 3666. PubMed ID: 16330707
    [No Abstract]   [Full Text] [Related]  

  • 36. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
    Schillaci G; Verdecchia P
    Ital Heart J Suppl; 2000 Sep; 1(9):1215-7. PubMed ID: 11140297
    [No Abstract]   [Full Text] [Related]  

  • 37. ALLHAT, or the soft science of the secondary end point.
    Messerli FH
    Ann Intern Med; 2003 Nov; 139(9):777-80. PubMed ID: 14597462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and heart failure: the ALLHAT imperative.
    Rodeheffer RJ
    Circulation; 2011 Oct; 124(17):1803-5. PubMed ID: 22025634
    [No Abstract]   [Full Text] [Related]  

  • 39. [ALLHAT].
    Ando K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():402-7. PubMed ID: 16981570
    [No Abstract]   [Full Text] [Related]  

  • 40. [After the ALLHAT trial, what do we know about treatment for hypertension that we did not know before?].
    González-Juanatey JR
    Rev Esp Cardiol; 2003 Jul; 56(7):642-8. PubMed ID: 12855144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.